Y-mAbs Therapeutics Executive Compensation (FY24)
YMAB · Executive and director compensation, fiscal 2023 to 2024
The paid brief on Y-mAbs Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): July 15, 2025
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
106 figures on this page: 101 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
More on Y-mAbs Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Rossi: $3,110,553 → $4,557,590 (46.5% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Y-mAbs Therapeutics' chief executive and what were they paid?
Total compensation for Michael Rossi, President and Chief Executive Officer, came to $4,557,590 in fiscal 2024. Rossi's total moved 46.5% higher from the $3,110,553 reported for fiscal 2023.
What was Y-mAbs Therapeutics' say-on-pay result?
For fiscal 2024, the say-on-pay proposal drew 87.6% support at the meeting held July 11, 2025.
Which companies are in Y-mAbs Therapeutics' peer group?
Companies named in the disclosed peer group include Aadi Bioscience, Inc., Agios Pharmaceuticals, Inc., Arcus Biosciences, Inc., Atara Biotherapeutics, Inc. and BioCryst Pharmaceuticals, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Rossi President and Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Thomas Gad Founder, Chief Business Officer and Vice Chairman of the Board of Directors | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Rossi President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Peter Pfreundschuh Executive Vice President, Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Thomas Gad Founder, Chief Business Officer and Vice Chairman of the Board of Directors | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Michael Rossi | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Peter Pfreundschuh | RSU | ◇ | ◇ | — | — |
| Thomas Gad | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Mary Tagliaferri | ◇ | ◇ | ◇ | — | — | — | ◇ |
James I. Healy Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
David N. Gill | ◇ | ◇ | ◇ | — | — | — | ◇ |
Laura J. Hamill | ◇ | ◇ | ◇ | — | — | — | ◇ |
Johan Wedell-Wedellsborg | ◇ | ◇ | ◇ | — | — | — | ◇ |
Ashutosh Tyagi | ◇ | ◇ | ◇ | — | — | — | ◇ |
Dr. Gérard Ber | ◇ | — | — | — | — | — | ◇ |
Thomas Gad and Michael Rossi served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as RSUs and Stock Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Aadi Bioscience, Inc. symbol not shown
- Agios Pharmaceuticals, Inc. AGIO
- Arcus Biosciences, Inc. RCUS
- Atara Biotherapeutics, Inc. ATRA
- BioCryst Pharmaceuticals, Inc. BCRX
- bluebird bio, Inc. BLUE
- Deciphera Pharmaceuticals, Inc. DCPH
- G1 Therapeutics, Inc. GTHX
- Heron Therapeutics, Inc. HRTX
- Iovance Biotherapeutics, Inc. IOVA
- Karyopharm Therapeutics Inc. KPTI
- MacroGenics, Inc. MGNX
- Puma Biotechnology, Inc. PBYI
- Rhythm Pharmaceuticals, Inc. RYTM
- Rigel Pharmaceuticals, Inc. RIGL
- SpringWorks Therapeutics, Inc. SWTX
- Travere Therapeutics, Inc. TVTX
- UroGen Pharma Ltd. URGN
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | July 11, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 11, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 8, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 9, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 10, 2021 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Y-mAbs Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Y-mAbs Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
106 figures on this page: 101 cited to the filing that reported them, 5 calculated from figures it prints.
101 cited to the filing
5 calculated from the filing
Documents cited
- 0001104659-25-068099
- 0001558370-25-008299Director Compensation · Outstanding Equity Awards at 2024 · Summary Compensation Table
- 0001104659-24-071250
- 0001558370-24-006094Summary Compensation Table
- 0001104659-23-070029
- 0001104659-22-070538
- 0001104659-21-080826
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Y-mAbs Therapeutics executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/YMAB (accessed 2026).
Short form: data: Velarion
The paid brief for Y-mAbs Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Y-mAbs Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Y-mAbs Therapeutics discloses
The companies named in YMAB's own disclosed peer group.
Agios Pharmaceuticals, Inc.Arcus Biosciences, Inc.Atara Biotherapeutics, Inc.BioCryst Pharmaceuticals, Inc.bluebird bio, Inc.Deciphera Pharmaceuticals, Inc.Heron Therapeutics, Inc.Iovance Biotherapeutics, Inc.Karyopharm Therapeutics Inc.MacroGenics, Inc.Puma Biotechnology, Inc.Rhythm Pharmaceuticals, Inc.Rigel Pharmaceuticals, Inc.SpringWorks Therapeutics, Inc.Travere Therapeutics, Inc.UroGen Pharma Ltd.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}